Bangalore, India, Jan 30: Strides Pharma Science Ltd today announced its consolidated financial results for the quarter (Q3 FY26) and nine months (9MFY26) ended December 31, 2025, reflecting strong growth across key markets and robust profitability.
The company reported a revenue of ₹11,946 million for Q3 FY26, a 3.6% year-on-year increase. Absolute gross margin grew 8.6% YoY to ₹7,317 million, with gross margin expanding by 280 basis points to 61.2%. EBITDA for the quarter increased 12.2% YoY to ₹2,359 million, delivering an EBITDA margin of 19.8%, up 160 basis points from the same period last year. Ex-US market revenue demonstrated strong growth of 20% YoY. Operational PAT rose 38.6% YoY to ₹1,282 million, with operational EPS at ₹13.9. Reported PAT stood at ₹2,081 million.
For the nine months ended December 31, 2025, revenue reached ₹35,352 million, up 4.7% YoY, while gross margin increased 11.6% to ₹21,127 million, with a margin of 59.8%. EBITDA for 9MFY26 stood at ₹6,856 million, up 17.2% YoY, and operational PAT reached ₹3,824 million, reflecting a 65% YoY growth, with operational EPS at ₹41.5. Operational PAT excludes exceptional items and one-time income. FY25 numbers have been restated following the demerger of the Softgel business.
Badree Komandur, MD & Group CEO, said,
“Strides continues to deliver a strong performance in Q3 FY26, led by growth in Other Regulated Markets and Growth Markets. Our continued focus on profitability resulted in healthy expansion of gross and EBITDA margins. Operational PAT and EPS rose nearly 38% YoY, highlighting our consistent execution while investing in sustainable, long-term growth. We are also pleased to welcome Peter Hardwick as CEO of our North America business; his experience and strategic insight will be critical in driving our growth in this region. Our commitment to ESG remains strong, with an improved S&P Global Corporate Sustainability Assessment score of 80, up five points from last year.”